Annals of Oncology 10:1163-1170, 1999
© 1999 European Society for Medical Oncology
review-article |
The influence of familial and hereditary factors on the prognosis of breast cancer
Departments of Medicine, Human Genetics and Oncology, McGill University Montréal, Québec, Canada
Correspondence to: P. O. Chappuis, Division of Medical Genetics, Room L10-120/Montreal General Hospital, 1650 Avenue Cedar, Montréal, Québec H3G 1A4, Canada, E-mail: pchappui{at}is.muhc.mcgill.ca
Background: Family history is a well recognized risk factor for breast cancer, but its impact in terms of breast cancer survival is uncertain. The recent identification of breast cancer predisposing genes has provided new clinical insights in this field.
Design: English literature identified through Medline between 1976 and February 1999 was reviewed including search terms: breast cancer, survival, prognosis, family history, genetics, BRCA1, BRCA2, and related articles.
Results: Publications were divided into three categories.Family history-based studies: eighteen articles were reviewed. Four studies showed a statistically significant better survival in patients with a family history of breast cancer, and two studies demonstrated a significantly worse prognosis in this context. The remaining articles showed no significant difference. Linkage studies: Two studies based on linkage to BRCA1 found that overall survival was better in linked families. A third one concluded to a worse outcome in BRCA2-linked tumors. Mutation-based studies: 10 studies looking at the association between germ-line mutations in BRCA1/BRCA2 and clinical outcomes were reviewed. Eight articles reported no significant difference in outcome, whereas two studies showed a worse outcome in patients with mutations.
Conclusions: Conflicting data exist as to whether the prognosis of familial or hereditary breast cancer differs from that of sporadic cases. Some of the discrepancies may be explained by methodological differences or biases. However, no studies showed a survival advantage for BRCA1 mutation carriers. This seems to indicate that BRCA1-related breast cancer is not associated with a survival advantage, and that in fact, certain BRCA1 germline mutations confer a worse prognosis. However, to adequately answer this question, more efficient molecular tools to identify all the genetic changes responsible for breast cancer predisposition, and large cohort studies to evaluate their clinical consequences, are needed.
BRCA1, BRCA2, breast cancer, family history, survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Leu, K. Czene, and M. Reilly The Impact of Truncation and Missing Family Links in Population-based Registers on Familial Risk Estimates Am. J. Epidemiol., December 15, 2007; 166(12): 1461 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Jacobi, N. J.D. Nagelkerke, J. C. van Houwelingen, and G. H. de Bock Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven BRCA1/BRCA2 Mutations: a Simulation Study. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. M. Brekelmans, C. Seynaeve, M. Menke-Pluymers, H. T. Bruggenwirth, M. M. A. Tilanus-Linthorst, C. C. M. Bartels, M. Kriege, A. N. van Geel, C. M. G. Crepin, J. C. Blom, et al. Survival and prognostic factors in BRCA1-associated breast cancer Ann. Onc., March 1, 2006; 17(3): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G H de Bock, M Schutte, E M M Krol-Warmerdam, C Seynaeve, J Blom, C T M Brekelmans, H Meijers-Heijboer, C J van Asperen, C J Cornelisse, P Devilee, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant J. Med. Genet., October 1, 2004; 41(10): 731 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Verkooijen, G. Fioretta, P. O. Chappuis, G. Vlastos, A. P. Sappino, S. Benhamou, and C. Bouchardy Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results Ann. Onc., February 1, 2004; 15(2): 350 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D. Foulkes, I. M. Stefansson, P. O. Chappuis, L. R. Begin, J. R. Goffin, N. Wong, M. Trudel, and L. A. Akslen Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer J Natl Cancer Inst, October 1, 2003; 95(19): 1482 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Chappuis, L. Kapusta, L. R. Begin, N. Wong, J.-S. Brunet, S. A. Narod, J. Slingerland, and W. D. Foulkes Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer J. Clin. Oncol., December 15, 2000; 18(24): 4045 - 4052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Verhoog, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, and J. G. M. Klijn Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients J. Clin. Oncol., November 1, 2000; 18(90001): 119s - 124. [Abstract] [Full Text] [PDF]
|
|